Candidiasis Treatment Market: Current Trends and Growth Forecast
Candidiasis, a fungal infection caused by Candida, is on the rise, primarily among individuals with pre-existing medical conditions that compromise their immune systems. Candida is a common inhabitant of the human body, particularly on the skin and in the mouth. The most prevalent species responsible for infections include C. glabrata, C. albicans, C. tropicalis, C. parapsilosis, and C. krusei. Various forms of candidiasis exist, including invasive infection, oropharyngeal candidiasis (commonly known as thrush), cutaneous candidiasis, vaginal yeast infection, and oesophageal candidiasis.
Recent studies have shown that nearly 20% of women typically have Candida in the vagina without issue. However, it can become problematic if it overgrows due to factors such as hormonal changes or compromised immunity.
Prevalence of Multiple Types of Candidiasis Augments Need for Effective Candidiasis Treatment
Oropharyngeal candidiasis, the most common fungal mouth infection, presents a significant market growth opportunity. Approximately 6% of infants under one month old are affected by oral candidiasis, while around 20% of cancer patients undergoing chemotherapy and 20% of AIDS patients develop this oral infection. Invasive candidiasis ranks as the fourth most common cause of bloodstream infections among hospital patients in the US. Between 2013 and 2017, the average incidence was approximately nine cases per 100,000 people, varying significantly by geographic location and patient population. Vaginal candidiasis, one of the most severe fungal infections, results in approximately 1.4 million doctor office visits annually in the US alone. About three-quarters of women experience at least one yeast infection during their lifetime, with nearly 50% of AIDS patients developing oesophageal candidiasis alongside other oesophageal conditions.
Lack of Effective Candidiasis Treatments and Rising Awareness Drive Demand
The global candidiasis therapeutics market is witnessing robust growth, driven by the increasing number of candidiasis infection cases worldwide and growing awareness about available treatment options. According to the Center for Disease Control and Prevention (CDC), approximately 46,000 cases of healthcare-associated invasive candidiasis occur annually in the US, making candidemia one of the most common bloodstream infections in the country. CDC estimates indicate that around 25,000 cases of candidemia occur nationwide each year, with up to 25% mortality observed in hospitalized patients with candidemia. Other key market drivers include rising government spending on fungal disease research and development, off-label drug usage, limited effective antifungals, and the historical lack of reliable treatments.
Growing Antifungal Resistance Presents Challenges
Candida antifungal drugs are experiencing growing resistance, particularly in Candida species such as Candida parapsilosis, Candida auris, and Candida glabrata. Echinocandin resistance, in particular, is a cause for concern, especially in C. glabrata. Additionally, Candida auris poses a serious public health challenge due to its high resistance rates to antifungal drugs like fluconazole and amphotericin B. The ease of spread in healthcare facilities further compounds the issue.
Growing R&D Activities Support Market Growth
Research and development efforts to develop novel treatment options for candidiasis are on the rise. Various government and private institutions worldwide are actively working on projects to combat candidiasis. Recent developments include the effectiveness of combination therapy (antifungal + antibacterial) against multidrug-resistant Candida auris and the development of chitosan nano formulations for delivering antifungal agents for the treatment of vaginal candidiasis.
Azoles Dominate the Antifungal Drug Class
Various drug classes are prescribed for candidiasis treatment, with azoles being the most sought-after. Triazole agents, including fluconazole, itraconazole, terconazole, butoconazole, econazole, and tioconazole, are the preferred choices. Recently developed triazoles, such as voriconazole, posaconazole, and ravuconazole, have proven effective against fluconazole-resistant strains and shown high efficacy in clinical studies.
Key Players in Global Candidiasis Treatment Market
Key companies competing in the global candidiasis treatment landscape include Amplyx Pharmaceuticals Inc., Astellas Pharma Inc., NovaDigm Therapeutics Inc., Merck KGaA, SCYNEXIS, Inc., Viamet Pharmaceuticals Holdings, LLC, Mycovia Pharmaceuticals Inc., Novabiotics Limited, Bayer AG, Basilea Pharmaceutica Ltd., Grupo Ferrer Internacional, S.A., Pacgen Life Science Corporation, NovaDigm Therapeutics, Inc., Cidara Therapeutics, Inc., and Pfizer, Inc.
The global candidiasis treatment market is witnessing substantial growth driven by an expanding patient population with pre-existing conditions, a need for effective treatments, and growing research and development efforts. As awareness increases and innovative therapies emerge, the market is expected to continue its upward trajectory.
Global Industry Analysis (2018 – 2021) – Growth Trends and Market Forecast (2022 – 2029) https://www.fairfieldmarketresearch.com/report/candidiasis-treatment-market
Visit Our Blogs:
Fairfield Market Research is a UK-based market research provider. Fairfield offers a wide spectrum of services, ranging from customized reports to consulting solutions. With a strong European footprint, Fairfield operates globally and helps businesses navigate through business cycles, with quick responses and multi-pronged approaches. The company values an eye for insightful take on global matters, ably backed by a team of exceptionally experienced researchers. With a strong repository of syndicated market research reports that are continuously published & updated to ensure the ever-changing needs of customers are met with absolute promptness.
Fairfield Market Research
UK +44 (0)20 30025888
USA (Toll-free) +1 (844) 3829746
This press release first seen on Brilad